Compare PDFS & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDFS | NBTX |
|---|---|---|
| Founded | 1992 | 2003 |
| Country | United States | France |
| Employees | N/A | 97 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2000 | 2018 |
| Metric | PDFS | NBTX |
|---|---|---|
| Price | $47.37 | $37.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $39.67 | $36.00 |
| AVG Volume (30 Days) | ★ 564.6K | 155.1K |
| Earning Date | 05-07-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $22.13 | $58.17 |
| Revenue Next Year | $18.92 | N/A |
| P/E Ratio | $214.32 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.37 | $9.32 |
| 52 Week High | $71.69 | $57.14 |
| Indicator | PDFS | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 46.41 |
| Support Level | $41.68 | $35.59 |
| Resistance Level | $51.99 | $41.06 |
| Average True Range (ATR) | 2.09 | 2.58 |
| MACD | 0.59 | -0.60 |
| Stochastic Oscillator | 82.45 | 26.60 |
PDF Solutions Inc provides products and services designed to empower organizations across the semiconductor and electronics ecosystem to connect, collect, manage, and analyze data about design, equipment, manufacturing, and test to improve the yield and quality of their products and operational efficiency. The Company's products, services, and solutions include proprietary software, physical intellectual property (IP) for integrated circuit (IC) designs, electrical measurement hardware tools, methodologies, and professional services.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.